Voyager Therapeutics Inc (VYGR) is now in the Undervalued zone, suggesting that its current forward PS ratio of 5.39 is considered Undervalued compared with the five-year average of -2.97. The fair price of Voyager Therapeutics Inc (VYGR) is between 15.65 to 17.08 according to relative valuation method. Compared to the current price of 4.15 USD , Voyager Therapeutics Inc By Undervalued By 73.48%.

Relative Value

Fair Zone

15.65-17.08

Current Price：4.15

73.48%

Undervalued

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is Voyager Therapeutics Inc (VYGR) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

Voyager Therapeutics Inc (VYGR) has a current Price-to-Book (P/B) ratio of 1.02. Compared to its 3-year average P/B ratio of 1.42, the current P/B ratio is approximately -28.41% higher. Relative to its 5-year average P/B ratio of 1.86, the current P/B ratio is about -45.27% higher. Voyager Therapeutics Inc (VYGR) has a Forward Free Cash Flow (FCF) yield of approximately -53.05%. Compared to its 3-year average FCF yield of -8.08%, the current FCF yield is approximately 556.41% lower. Relative to its 5-year average FCF yield of -18.70%, the current FCF yield is about 183.70% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for VYGR competitors is 75.24, providing a benchmark for relative valuation. Voyager Therapeutics Inc Corp (VYGR.O) exhibits a P/S ratio of 5.39, which is -92.84% above the industry average. Given its robust revenue growth of -45.73%, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of VYGR increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of VYGR in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is VYGR currently overvalued or undervalued?

Voyager Therapeutics Inc (VYGR) is now in the Undervalued zone, suggesting that its current forward PS ratio of 5.39 is considered Undervalued compared with the five-year average of -2.97. The fair price of Voyager Therapeutics Inc (VYGR) is between 15.65 to 17.08 according to relative valuation method. Compared to the current price of 4.15 USD, Voyager Therapeutics Inc is Undervalued By 73.48%.

What is Voyager Therapeutics Inc (VYGR) fair value?

VYGR's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Voyager Therapeutics Inc (VYGR) is between 15.65 to 17.08 according to relative valuation method.

How does VYGR's valuation metrics compare to the industry average?

The average P/S ratio for VYGR's competitors is 75.24, providing a benchmark for relative valuation. Voyager Therapeutics Inc Corp (VYGR) exhibits a P/S ratio of 5.39, which is -92.84% above the industry average. Given its robust revenue growth of -45.73%, this premium appears unsustainable.

What is the current P/B ratio for Voyager Therapeutics Inc (VYGR) as of Mar 02 2026?

As of Mar 02 2026, Voyager Therapeutics Inc (VYGR) has a P/B ratio of 1.02. This indicates that the market values VYGR at 1.02 times its book value.

What is the current FCF Yield for Voyager Therapeutics Inc (VYGR) as of Mar 02 2026?

As of Mar 02 2026, Voyager Therapeutics Inc (VYGR) has a FCF Yield of -53.05%. This means that for every dollar of Voyager Therapeutics Inc's market capitalization, the company generates -53.05 cents in free cash flow.

What is the current Forward P/E ratio for Voyager Therapeutics Inc (VYGR) as of Mar 02 2026?

As of Mar 02 2026, Voyager Therapeutics Inc (VYGR) has a Forward P/E ratio of -2.11. This means the market is willing to pay $-2.11 for every dollar of Voyager Therapeutics Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Voyager Therapeutics Inc (VYGR) as of Mar 02 2026?

As of Mar 02 2026, Voyager Therapeutics Inc (VYGR) has a Forward P/S ratio of 5.39. This means the market is valuing VYGR at $5.39 for every dollar of expected revenue over the next 12 months.

VYGR Valuation